Maris, J. M. Recent advances in neuroblastoma. N. Engl. J. Med. 3622202–2211 (2010).
Google Scholar
London, W. B. et al. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children’s Oncology Group early-phase trials. Cancer 1234914–4923 (2017).
Google Scholar
Pearson, A. D. J. et al. Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration. EUR. J. Cancer 157198–213 (2021).
Google Scholar
Moreno, L. et al. Outcome of children with relapsed or refractory neuroblastoma: a meta-analysis of ITCC/SIOPEN European phase II clinical trials. Pediatr. Blood Cancer 6425–31 (2017).
Google Scholar
Moreno, L. et al. Bevacizumab, irinotecan, or topotecan added to temozolomide for children with relapsed and refractory neuroblastoma: results of the ITCC-SIOPEN BEACON-Neuroblastoma trial. J. Clin. Oncol. 421135–1145 (2024).
Google Scholar
Mody, R. et al. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. Lancet Oncol. 18946–957 (2017).
Google Scholar
Mody, R. et al. Irinotecan, temozolomide, and dinutuximab with GM-CSF in children with refractory or relapsed neuroblastoma: a report from the Children’s Oncology Group. J. Clin. Oncol. 382160–2169 (2020).
Google Scholar
Lerman, B. J. et al. Progression-free survival and patterns of response in patients with relapsed high-risk neuroblastoma treated with irinotecan/temozolomide/dinutuximab/granulocyte-macrophage colony-stimulating factor. J. Clin. Oncol. 41508–516 (2023).
Google Scholar
Olgun, N. et al. Dinutuximab β plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: a single-center experience. Front. Oncol. 121041443 (2022).
Google Scholar
Raiser, P. et al. Chemo-immunotherapy with dinutuximab β in patients with relapsed/progressive high-risk neuroblastoma: does chemotherapy backbone matter? EUR. J. Cancer 202114001 (2024).
Google Scholar
Gray, J. et al. BEACON-Immuno: results of the dinutuximab β (dB) randomization of the BEACON-Neuroblastoma phase 2 trial—a European Innovative Therapies for children with cancer (ITCC–International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN) trial. J. Clin. Oncol. 4010002 (2022).
Google Scholar
Del Bufalo, F. et al. GD2-CART01 for relapsed or refractory high-risk neuroblastoma. N. Engl. J. Med. 3881284–1295 (2023).
Google Scholar
Morgenstern, D. A. et al. Risk stratification of high-risk metastatic neuroblastoma: a report from the HR-NBL-1/SIOPEN study. Pediatr. Blood Cancer 65e27363 (2018).
Google Scholar
Campbell, K. et al. Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: a report from the Children’s Oncology Group. Cancer 1234224–4235 (2017).
Google Scholar
Yanik, G. A. et al. Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children’s Oncology Group. J. Nucl. With. 54541–548 (2013).
Google Scholar
Moreno, L. et al. A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high-risk neuroblastoma: an International Neuroblastoma Risk Group project. Pediatr. Blood Cancer 68E28794 (2021).
Google Scholar
Lee, D. W. et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124188–195 (2014).
Google Scholar
Hayden, P. J. et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann. Oncol. 33259–275 (2022).
Google Scholar
Quintarelli, C. et al. Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma. Night. With. 31849–860 (2025).
Google Scholar
Chok, R. & Ramakrishna, S. Allogeneic approach unlocks CAR T cell benefits in solid tumors. Night. With. 31733–734 (2025).
Google Scholar
Mora, J. et al. Clinical and pathological evidence of anti-GD2 immunotherapy induced differentiation in relapsed/refractory high-risk neuroblastoma. Cancers (Basel) 131264 (2021).
Google Scholar
Park, J. R. et al. Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: a consensus statement from the National Cancer Institute Clinical Trials Planning Meeting. Cancer 1283775–3783 (2022).
Google Scholar
Straathof, K. et al. Antitumor activity without on-target off-tumor toxicity of GD2-chimeric antigen receptor T cells in patients with neuroblastoma. Sci. Transl. Med. 12eabd6169 (2020).
Google Scholar
Heczey, A. et al. CAR T cells administered in combination with lymphodepletion and PD-1 inhibition to patients with neuroblastoma. Mol. Ther. 252214–2224 (2017).
Google Scholar
Louis, C. U. et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 1186050–6056 (2011).
Google Scholar
Steffin, D. et al. Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature 637940–946 (2025).
Google Scholar
Zhou, X. et al. Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. Blood 1254103–4113 (2015).
Google Scholar
Applebaum, M. A. et al. Neuroblastoma survivors are at increased risk for second malignancies: a report from the International Neuroblastoma Risk Group Project. EUR. J. Cancer 72177–185 (2017).
Google Scholar
Haghiri, S. et al. Long-term follow-up of high-risk neuroblastoma survivors treated with high-dose chemotherapy and stem cell transplantation rescue. Bone Marrow Transpl. 561984–1997 (2021).
Google Scholar
Bird, N., Scobie, N., Palmer, A. & Ludwinski, D. To transplant, or not to transplant? That is the question. A patient advocate evaluation of autologous stem cell transplant in neuroblastoma. Pediatr. Blood Cancer 69E29663 (2022).
Google Scholar
Quintarelli, C. et al. Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma. Oncoimmunology 7E1433518 (2018).
Google Scholar
Park, J. R. et al. Revisions to the International Neuroblastoma Response Criteria: a consensus statement from the National Cancer Institute Clinical Trials Planning Meeting. J. Clin. Oncol. 352580–2587 (2017).
Google Scholar
Ladenstein, R. et al. Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials. Eur. J. Nucl. Med. Mol. Imaging 45292–305 (2018).
Google Scholar
Lewington, V. et al. 123I-mIBG scintigraphy in neuroblastoma: development of a SIOPEN semi-quantitative reporting method by an international panel. Eur. J. Nucl. Med. Mol. Imaging 44234–241 (2017).
Google Scholar
Zeytin, H. E., Tripathi, P. K., Bhattacharya-Chatterjee, M., Foon, K. A. & Chatterjee, S. K. Construction and characterization of DNA vaccines encoding the single-chain variable fragment of the anti-idiotype antibody 1A7 mimicking the tumor-associated antigen disialoganglioside GD2. Cancer Gene Ther. 71426–1436 (2000).
Google Scholar
Schemper, M. & Smith, T. L. A note on quantifying follow-up in studies of failure time. Control Clin. Trials 17343–346 (1996).
Google Scholar
